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ABSTRACT 
Human adenovirus (HAdV) has been associated with acute respiratory disease (ARD) in adult 
and pediatric patients in Egypt.  Worldwide, adenovirus of species B, C, and E are 
predominantly associated with ARD.  As part of an influenza-like illness (ILI) surveillance 
program in Egypt, we isolated 99 adenoviruses from 2003 to 2010.  Initial identification of the 
isolates was accomplished with immunofluorescence assays (IFAs) and then confirmed with 
multiplex and monoplex PCR protocols.  Of the 99 isolates, 39 were species B, 54 were species 
C, and 1 was species E.  Additionally, 5 isolates represented co-infections of both HAdV-B and 
HAdV-C.  Molecular typing by PCR and sequencing of the hexon gene allowed the 
identification of the serotypes of the HAdV-B isolates as follows: 17 isolates were Ad-3, 14 were 
Ad-7, 8 were Ad-11a. For the species C HAdV, 19 isolates were Ad-1, nine were Ad-2, 13 were 
Ad-5 and 12 were Ad-6. One sample in this group also represented a co-infection of Ad-5/Ad-6.  
The serotypes of the five HAdV-B/HAdV-C co-infections were Ads (3+1) for three cases, while 
the other two were Ads (3+5) and Ads (3+2).  In contrast to previous studies in Egypt, we 
observed a higher number of HAdV-Cs which was recovered largely from a pediatric population. 
To reveal any recombination events in the AdV-C species isolates, we sequenced the fibre and 
the HVR-7 of the hexon genes and detected an Ad-2/Ad-6 recombination. The isolates which 
showed recombination events had the fibre of Ad-6 and the HVR-7 of Ad-2. For the HAdV-C 
fibre genes sequenced, the tail region was highly conserved (100% homology of amino acids) 
whereas the shaft and knob regions showed a high degree of heterogeneity at the nucleotide and 
amino acids levels. Additional studies are currently underway to determine novel markers of 
antiviral resistance, and to define possible vaccine candidate components that would be effective 
for the region. 
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ABBREVIATIONS 
aa  amino acid 
Ad  Adenovirus (used for serotypes) 
ARD  Acute respiratory disease 
ATCC  American Type Culture Collection (ATCC) 
CAR  Coxsackie-adenovirus receptor 
CPE  Cytopathic Effect 
DMEM Dulbecco’s Modified Eagle Medium 
DNA  Deoxyribonucleic acid  
DPPC  Dipalmitoyl phos(143)phatidylcholine 
GON  Group of Nine 
HAdV  Human adenoviruses (used for species) 
HVR  Hypervariable region 
IFA   Immunofluorescence assay 
ILI  Influenza-like illness 
LLC-MK2 Rhesus monkey kidney cells 
MDCK Madin-Darby canine kidney 
MHC-1            Major histocompatibility complex-1 
NAMRU-3      Naval Medical Research Unit No. 3  
NCI-H2929     Human, black, lung, carcinoma, mucoepidermoid 
PCR  Polymerase chain reaction 
VCAM-1 Vascular cell adhesion molecule 1 
VTM  Viral transport medium 
WHO  World Health Organization 
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LITERATURE REVIEW 
 Human adenovirus (HAdV) was first described by Rowe et al. in 1953 (93).  As the name 
suggests, the virus was isolated from explant cultures of human adenoid tissue that demonstrated 
unusual cellular activity in tissue culture (44, 93). Under the current classification guidelines of 
the International Commitee on Taxononomy of Viruses (ICTV), adenoviruses belong to the 
genus Mastadenovirus, family Adenonoviridae (8). These viruses  consist of non-enveloped, 
linear,
 
non-segmented, double-stranded DNA (dsDNA) with a genome size
 
ranging from 30kb to 
45kb and can infect a wide variety of hosts (7, 21, 40-42, 89, 110, 111, 133, 134, 138, 141). 
Human adenoviruses (HAdVs) are divided into seven species (A to G). Species B is further
 
subdivided into B1 and B2 (112). The members of the species are further subdivided into fifty-
two serotypes or genotypes (4, 22, 53, 125). The most recent serotype designation, Ad-52, 
proposed by Jones et al. (53) continues to be controversial in nature with some experts in the 
field considering it to be more of an Ad-41 serotype variant.  
 Historically,  HAdVs were speciated and serotyped according to the following criteria: 
GC content in genome, growth characteristics, red blood cell agglutination assays, oncogenecity 
in rodents, host range, and tropism (Table 1)(20, 48, 123, 137). Presently, immunological (e.g. 
hemagglutination inhibition reactions and immunoflourescence) or molecular techniques (e.g. 
full genome sequencing, Restriction Fragment Length Polymorphism (RFLP) or Restriction 
Enzyme Analysis (REA)) are the diagnostic modalities of choice (43, 52, 53, 65, 126, 127, 129, 
130). Hemagglutination methods take advantage of the fact that the HAdV fibre knob protein 
carries a type-specific gamma determinant which fortuitously binds to red blood cells causing 
their agglutination. This action can be abrogated by the addition of type-specific antiserum. 
Similarly, major antigenic determinants, or the epsilon (ε) determinants, present on the viral 
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hexon protein, and to a lesser extent, the minor γ antigenic determinants on the fibre knob are 
used for serotyping (8, 66, 80, 98, 99, 108). Advances in molecular biology and genomics, 
especially with respect to the polymerase chain reaction and commercially available restriction 
enzymes, have added more efficient and sensitive techniques for detecting unknown isolates and 
for characterizing the fibre and the hexon genes (4, 64, 75-77, 108). 
Adenovirus structure and surface elements 
 Adenoviruses have an icosahedral capsid with a diameter of about 90 nm (8, 99, 114), as 
shown by x-ray crystallography and cryo-electron microscopy.  The capsid is composed of three 
major
 
proteins, hexon (II), penton base (III) and a knobbed fibre
 
(IV). There are also a number of 
other minor proteins (8, 98, 99, 144) (figure 1).  
Hexon  
 The hexon is a pseudo-hexagonal trimer. Each capsid has 240 copies distributed over the 
20 faces of the protein coat (8). Hexon proteins are divided into four types: H1, H2, H3 and H4. 
H1 surrounds the penton protein at the vertices (peripentonal hexons). The rest are arranged in 
“Group of nine” or “GON” on each face of the icosahedral surface (8).  
Hexon sizes vary with different serotypes. For example, Ad-2 has the largest hexon; it is 
composed of 967 aa (98). Interestingly, each hexon molecule can have up to nine hypervariable 
regions.  HVRs are divided amongst 2 loops; Loop 1 (L1) contains 6 HVRs (HVR 1-6) whereas 
L2 contains the HVR-7 (8, 98). At least one or more of these regions encode type specific 
antigens responsible for inciting adenovirus neutralizing antibodies (18, 34, 66, 87, 92, 98, 105, 
117, 121, 124).  As mentioned previously, this immunological feature figures prominently in the 
groups’ identification and phylogenetic classification schemes.  Other than shielding the virus 
genome in concert with other structural components during the virion’s passage to the host cell 
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nucleus and interacting with coagulation
 
factor X during hepatocellular infections (58), the exact 
role of the hexon in virulence has not yet been fully elucidated. 
Penton Base 
 The penton protein, or stabilizing protein, is located at each of the twelve vertices of the 
icosahedral capsid. It is made up of the homopentameric penton base and the homotrimeric fibre 
which protrudes from its base. Additionally, it binds to nearby capsid proteins, H1 and 
polypeptide IIIa.  Due to these features, it is one of the first segments of the virus that interacts 
with the host cell (8, 98, 143). The fibre binds non-covalently to the penton base utilizing the 
conserved sequence, FNPVVPYD, near its N-terminal. Hydrogen bonds and salt bridges support 
the binding strength (80, 118, 119). The penton base is highly susceptible to pH fluctuations, 
heat, ionic strength variations and trypsin (91, 98).  
Fibre 
 The fibre monomer is made up of three distinct regions: tail, shaft and the knob. The fibre 
tail is located at the N-terminal of the polypeptide. This region, which consists of about 45 
residues, is conserved among different HAdV species and some studies indicate that only 11 
residues in the tail are required to make a stable binding to the penton base (33, 98, 144).   
 The fibre length, represented predominantly by the shaft, differs from one serotype to 
another and is based on the number of amino acids pseudorepeats. Each pseudorepeat consists of 
15-20 residues. The number of repeats may range from three up to twenty-three repeats. For 
instance,  Ad-35 has 5.5 pseudorepeats. In contrast, Ad-12 has 22.5 (80). The amino acids 
repeats comprise antiparallel β-strands which are connected by β-turns, resulting in the 
microscopically observed spiral shaft morphology (33, 51, 80, 95). The difference in fibre-length 
and flexibility (or shaft binding potential) among species/serotypes determine HAdV 
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pathogenicity and host range since the fibre protein interacts with different cellular receptors for 
attachment of HAdV during infections (33, 80, 95, 98, 112, 143). The flexibility is due to hinge-
like connections which exist between the knob and the shaft. HAdV-D lack the hinge-like 
conformations described in the other species. As a result, HAdV-D’s stiff fibres require supple 
receptors for cellular entry (80). 
 At the fibre C-terminus, 180 residues form the globular knob (figure 2). This C-terminus 
is responsible for interaction with cellular receptors due to its external projection (9, 66, 80, 98, 
112). The fibre knob can have both lateral and apical interactions with cellular receptors. The 
amino acid sequences of the exposed loops (e.g. AB, CD, HI and DG loops) of the knob differ 
from one species of HAdV to another. This can affect tissue tropism as well as possible clinical 
manifestations and outcomes in human patients (33, 47, 80, 85, 98, 112, 113, 144).  
Polypeptide IIIa 
 This protein is located below the penton in the capsid. It binds to neighbouring proteins: 
the penton, hexon, protein VI and to core proteins (11, 105). There are about 60 molecules in the 
virus; 5 clusters at each viral vertex (103). It has a helical structure (about 14 helices) (99, 105). 
Polypeptide IIIa binds to the penton base through its N-terminal side. Using 2D-gel 
electrophoresis (IEF followed by SDS-PAGE) indicates that this protein is highly 
phosphorylated and thus may play a role in promoting virus disassembly early in infection (100). 
Polypeptide VI 
 This protein consists of 2 alpha-helices (69). There are about 360 protein VI molecules in 
the viral particle (116). Polypeptide VI interacts with polypeptide IIIa, penton base, H1 and 
polypeptide V. Polypeptide VI facilitates viral particle transfer to the nucleus after endosome 
acidification (98, 132, 136, 140). 
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Polypeptide VIII 
 This protein is found below the capsid in two locations; five molecules form a circular 
structure around the H1 molecules connecting them to the GON and another three molecules 
form a  ring giving a higher stability to the hexons in the GONs. One hundred and twenty copies 
of protein VIII exist in each virus particle and lend stability to the viral apices by forming a bond 
between the H1 and the other hexons in the capsid (98).  
Polypeptide IX 
 This protein forms “coiled-coils” and its N-terminal is located in the centre of each viral 
capsid face. The C-terminus is formed of a bundle of four helices; one α-helix binds the 
Hypervariable region 4 (HVR4) which is found in loop one of the hexon as mentioned earlier 
(67, 98, 105). Two hundred and fourty polypeptide IX molecules exist in each virus particles. 
This protein is thermostable and as a result, is thought to stabilize of the capsid (12, 98) 
Core proteins 
Polypeptide V  
 Little is published about the structure of Polypeptide V. One hundred and sixty copies are 
located in the viral core accompanying polypeptide VII and the viral genome. A strong 
association occurs between this protein and polypeptide VI (68, 98).  
Polypeptide VII 
 Polypeptide VII is a basic protein that associates strongly with the viral genomic DNA. 
More than 800 molecules exist in each virus dispersed over the viral genome. Polypeptide VII 
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signals viral targeting to the nucleus. After viral import to the nucleus, other cellular proteins 
(e.g. importins, Histone1, transportin) bind to polypeptide VII which leads to changes in viral 
DNA conformation. Polypeptide VII prevents premature viral transcription (37, 98, 139). 
Mu protein “Polypeptide X”  
 Mu protein “Polypeptide X” is a basic protein with similar properties to those of 
protamines. There are approximately 100 molecules present in the virus. They have very similar 
properties to protamines. Mu protein can, as a precursor (polypeptide X), modify early viral 
proteins (E2) transcription. The precursor (preMu) also is thought to condense the viral 
“prechromatin” utilizing its basic motifs (98).  
Terminal protein (TP)  
 As the name implies, this protein is covalently linked to the 5’Terminal of the viral DNA. 
Interaction with other proteins is still not known (90, 98). 
Polypeptide IVa2   
 Only a few copies are present in each particle. This protein attaches to certain sites on the 
viral DNA (102). The main function of this protein seems to be virion packaging during virus 
assembly. 
Adenain protease 
 The phosphorylated protease adenain is required for the production of infectious virions; 
mutants lacking this protease cannot effectively infect and disseminate (101). It digests the 
procapsid, precursor proteins to produce the functional proteins VIII, VI, VII and IIIa and the 
precursor of the core proteins (5). Protease number ranges from 10 to 70 per virion (98).  
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Human adenovirus infection  
 HAdVs are primarily transmitted via aerosol droplets but fecal matter and fomites can 
play a role as well.  HAdVs target lymphoid tissue: tonsils, adenoids, and Peyer’s patches. The 
virus uses a two-step mechanism for cellular entry.  The knob portion of the fibre facilitates the 
adsorption of virus to target cell receptors, followed by the interaction of the penton with a 
second internalizing receptor. The RGD
 
motif (Arg-Gly-Asp) exposed on the penton base 
interacts with cellular v integrins (115, 135) and mediates clathrin-mediated endocytosis for 
viral entry. Interestingly, the RGD motif is not found in the HAdV-F species (Ad-40 and Ad-41) 
(135). The targeted cellular receptors can include the coxsackie/adenovirus receptor
 
(CAR), 
heparan sulfate glycosaminoglycans (HS-GAGs), CD46, CD80 and CD86 (B7-1 and B7-2), 
sialic acid (α(2,3)-linked sialic acid), integrins αMβ2 and αLβ2, α2 domain of the major 
histocompatibility complex-1 (MHC-1), vascular cell adhesion molecule 1 (VCAM-1), and 
dipalmitoyl phophatidylcholine (DPPC) (16, 143). In general, HAdV-A, C, E and F utilize  the 
coxsackie/adenovirus receptor and some HAdV-D serotypes interact with the “soluble CAR” 
(83, 98). HAdV-C species (Ad-2, 5) are the main types which utilize HS-GAGs and/or the sialic 
acid receptors for attachment via the KKTK motif in the fibre shaft (23, 143). HAdVs, which 
utilize CD46 for attachment, are HAdV-B (Ad-3, 11, 14, 16, 21 and 35) and HAdV-D (Ad-37, 
50)(143). The resulting manifestations of adenovirus disease in humans vary greatly, ranging 
from minor respiratory (B1, C, E), gastrointestinal (F) and ocular (B, D, E) infections to life 
threatening pneumonia, septicemia and endocarditis in immunocompromised patients (1, 2, 86, 
98).  
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Adenovirus prophylaxis 
 Adenoviruses have been studied extensively since their initial identification in the 1950s 
(10, 44, 93). Previous publications have focused extensively on recombinant adenovirus viruses 
used as vectors for such applications as gene therapy (46) or vaccine delivery system for other 
pathogens (19, 47, 64). In the past, anti-adenovirus vaccine compositions were sought largely to 
mitigate infection in US military recruit populations who appeared particularly susceptible to 
outbreaks of HAdV serotypes 4, and 7 (24, 31, 55, 72, 79, 96, 97, 107, 120, 122). Vaccine 
preparations for male US military recruits have included the initial bivalent (4 and 7) formalin-
inactivated monkey kidney whole cell extract and monovalent live oral preparations (types 4,7, 
and 21) derived from human diploid cells and packaged in enteric coated capsules. Vaccine 
administration choice to male recruits was based on guidance provided by the US Army 
Adenovirus Surveillance Program (25, 122). With cessation of the adenovirus immunization 
program in 1995, military posts have seen a recrudescence of adenovirus infections. Likewise, 
the global deployment of troops places units at increasing risk of exposure to circulating 
adenoviruses in their respective operational arenas.  
Adenovirus Epidemiology  
 The adenovirus related acute febrile respiratory diseases in the civilian population, 
inclusive of pediatric and adult populations, are caused mainly by HAdV-B, HAdV-C and 
HAdV-E (20, 94, 106, 109).  Approximately 60%  of HAdV infections in children and young 
adults are caused by HAdV-C (3, 32, 75, 109) and asymptomatic carriers may be the reason for 
the virus’ persistence in the population(13). HAdV-E (Ad-4) and HAdV-B (Ad-3,7,11,14,16, and 
21) tend to cause specific outbreaks of febrile respiratory illness, conjunctivitis, and pneumonia 
in crowded populations (e.g. academic lodging, public natatoriums, and military barracks) (49, 
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54, 55, 74, 88, 94).  HAdV-B2 infections occur as sporadic infections and target the urinary tract 
(98). However, some respiratory disease outbreaks have been attributed to HAdV-B2 serotypes 
Ad-11 and Ad-14 (15, 74, 97). Adenovirus outbreaks have been extensively documented in the 
US, UK,  China, Japan and South America (14, 17, 52, 56, 60, 81, 84, 104).  In comparison, a 
few studies have examined the role of adenovirus in causing respiratory or enteric disease in 
Egypt (27-30, 59, 75).  
 Co-infections with different serotypes have been shown to cause fatal infections in 
immunocompromised patients and to interfere with vaccine protection (62, 70).  Unfortunately, 
very few studies have actively sought to dissect out and describe co-infections.  In Egypt, only 
one known study was conducted to determine the serotypes of HAdVs affecting civilian out-
patients presenting with influenza-like illness from 1999-2002. Performing several multiplex and 
monoplex PCRs, Metzgar and his colleagues found fifteen coinfections of multiple adenoviral 
types, mainly HAdV B/C or multiple serotypes of HAdV-B. In addition, genomic recombination 
between different serotypes have been documented (26, 64, 70). Recombination events can either 
be interspecies (rare) or intraspecies.  Detection of recombination can be accomplished by 
sequencing more than one region of the HAdV genome and then using bioinformatics to 
determine if the region(s) belong to the same serotype. The most common regions scrutinized are 
HVR7 of the hexon gene and the fibre gene (26, 64, 70). Recombinant (intermediate) HAdVs 
have been involved in outbreaks and in some instances, the disease course was more severe than 
typically observed with a wild-type infection. Recombination events can potentially impact 
tissue tropism such that intermediate strains with different fibre translational products may 
shown an affinity to different cellular receptors (33, 64, 80).  In the 1970s,  Ad-19a caused an 
outbreak of keratoconjunctivitis in Europe and North America. Closer examination revealed that 
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the causative agent had acquired the fibre gene of Ad-37 which modified its pathogenicity and 
tissue tropism (6, 70, 128). Another example of a recombinant is Ad-7h. This intermediate strain 
consisted of an Ad-7 hexon but the fibre and E3 genes from an Ad-3. This strain was responsible 
for cases of severe respiratory disease in South America and Japan (39, 57).  
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THESIS OBJECTIVES 
 In this study, we sought to characterize adenoviruses isolated from oropharyngeal 
cultures obtained from patients who presented with influenza-like illness from 2003 to 2010. We 
were interested in determining the species and serotypes of circulating adenoviruses in Upper 
Egypt, Greater Cairo and the Delta regions. Additionally, we aimed to gain a better 
understanding of the contribution of adenovirus co-infections and recombination events to 
respiratory disease in paediatric and adult populations.  
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MATERIALS AND METHODS 
Sample collection.  
Adenovirus isolates (n=99) examined in this study were derived from oropharyngeal 
swabs (throat cultures) obtained from out-patients (ages 2 months to 56 years) who presented to 
eight different Egyptian hospitals from 2003 to 2010 and met the World Health Organization 
definition of influenza-like illness (ILI) symptoms. All the patients in this study presented with 
fever (38°C or higher). Other symptoms common among the patients included cough malaise, 
lassitude, headache and sore throat. The hospitals in greater Cairo included Imbaba Fever 
Hospital (Imbaba, Giza), Al-Gabarty Hospital (Mokatam, Cairo) and Helwan Fever Hospital 
(Helwan). The hospitals in Upper-Egypt include Menia Fever Hospital (Menia) and Aswan 
Fever Hospital (Aswan).  The remaining three belonged to the North coast and Delta region: 
Alexandria Fever Hospital (Alexandria), Damietta Fever Hospital (Damietta) and Sharquia Fever 
Hospital (Sharquia). Oropharyngeal swabs were placed in WHO viral transport medium (VTM). 
VTM was prepared at  the US Naval Medical Research Unit No. 3 (NAMRU-3) and contained 
veal infusion broth, bovine serum, gentamicin and amphotericin B. Clinical samples were placed 
in liquid N2 tanks until transported to NAMRU-3 and then maintained at -70°C until they were 
processed. 
 
Virus isolation and initial identification. 
Samples were treated with antibiotics (penicillin, streptomycin and gentamicin) and an 
antifungal agent (Amphotericin B) for ten minutes before inoculation to reduce cell culture 
contamination. 100µl of the each sample was inoculated in three cell lines: Madin-Darby canine 
kidney (MDCK)(ATCC# CCL-34) cells, NCI-H2929 (human, black, lung, carcinoma, 
mucoepidermoid)(ATCC# CRL-1848) and LLC-MK2 (rhesus monkey kidney cells) (ATCC# 
XIX 
 
CCL-7.1) in order to maximize recovery of respiratory viral pathogens. The growth media used 
for MDCK and LLC-MK2 was DMEM (Dulbecco's Modified Eagle Medium) while for  NCI-
H292 cells, it was RPMI. In all cases, 10% fetal bovine serum (FBS), 1% penicillin/streptomycin 
and 1% L-glutamine were supplemented. Samples were then inoculated on to 80-90% confluent 
cells. After inoculation, adsorption of the samples occurred for one hour and then maintenance 
media was added. Maintenance media for MDCK consisted of DMEM, 2% BSA, 1% 
penicillin/streptomycin, 1% L-glutamine, 2% HEPES buffer and trypsin/TPCK. Maintenance 
media for LLC-MK2 consisted of DMEM, 1% penicillin/streptomycin and 1% L-glutamine. 
Maintenance media for NCI-H292 consisted of RPMI, 1% penicillin/streptomycin and 1% L-
glutamine. Cell cultures were examined for cytopathic effect (CPE) over 12-14 days. 99 human 
adenovirus (HAdV) isolates were recovered from the aforementioned cell lines: 63 from NCI-
H292, 34 from LLC-MK2 and 2 from MDCK. HAdV initial identification was done by Indirect 
Immunoflourescence Antibody Test (IFA) using (Respiratory Viral Screen IFA Kit, LIGHT 
DIAGNOSTICS™, Millipore (Cat# 3105)). Positive and negative controls supplied with the kit 
were used for confirmation (Figure 3). After confirmation infected tissue culture fluid (ITCF) 
and cell lysates were collected and stored at -70°C for further processing. 
DNA extraction. 
DNA was extracted from 200µl of the ITCF and cell lysates (MagNA Pure LC Total 
Nucleic Acid Isolation Kit 192 Isolations). The One hundred µl DNA extracts were kept at -20°C 
and the remaining samples were refrozen at -70°C.  
Control strain for adenoviruses.  
Control strains for HAdV-B (Ad 3, 7, 21, 11, 14, 16 and 35), HAdV-C (Ad 1, 2, 5 and 6) 
and HAdV-E (4) serotypes were obtained from American Type Culture Collection (ATCC). 
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Amplification and detection of adenovirus species and serotypes.  
Primers used for identification, species determination and serotyping were obtained from 
previously published papers. For confirmation of HAdV, we used Ad universal primers (142). 
Determination of virus species was accomplished using BCE multiplex PCR with some 
modifications to the original described method (73, 75). The PCR reactions for HAdV-B 
determination was separated from that of HAdV-C and HAdV-E due to the occasional 
appearance of non-specific bands when using the AdV-BCE multiplex. Serotyping/genotyping of 
HAdV-B was carried out sequentially. A multiplex for Ad-3, 7 and 21 was done first (Figure 4) 
(50). Unidentified isolates were tested for Ad-11, Ad-14, Ad-16, and Ad-35 (74). HAdV-C 
serotyping was done using a one-step multiplex PCR for the four serotypes (3). Confirmation of 
HAdV-E infection was done using primers specific for Ad4 which could also differentiate 
between two important variants 4a and 4p according to the amplicon size (Table 2) (50). The 
aforementioned primers enabled determination of coinfections which were further confirmed by 
carrying out the above PCR reactions as monoplexes and by using primers targeting other 
genomic regions (142). 
Purification of the DNA-PCR product for sequencing.  
DNA bands with the desired size were extracted from gels using Qiagen Gel Extraction 
Kit
TM
.  
Sequencing of HVR7 and Fibre genes of HAdV-C isolates. 
Oligonucleotide primers used for sequencing the HVR7 are listed in Table 2. 
Oligonucleotide primers used for sequencing the fibre genes and designed in our laboratory are 
listed in Table 3. Sequencing was carried out using BigDye Terminator cycle sequencing kit 
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(Applied Biosystems, California) in ABI3130XL, Applied Biosystem (Applied Biosystems, 
California). 
Sequences editing and analysis. 
Sequencher V4.10.1software (Gene Codes, USA) was used for editing, cleaning and 
assembling the generated sequences. The edited sequences were then aligned using muscle 
wrapper application of Bioedit7.0.4.1 software. Phylogenetic trees were constructed using 
MEGA4 software utilizing the neighbour-joining method and maximum composition likelihood 
model for nucleotide substitution. Bootstrap analysis was implemented with 1000 replicates. 
Nucleotide sequence homology analysis was accomplished with the sequence identity matrix of 
the Bioedit7.0.4.1 software. 
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RESULTS 
Human Adenovirus B and C contribute to the morbidity of patients presenting with 
influenza-like illness (ILI) in Egypt.   
We hypothesized that human adenovirus infection may contribute to the morbidity of 
patients presenting with influenza-like illness from 2003-2010. We tested this hypothesis by 
screening influenza A negative samples by immunofluorescence assays (IFAs) and then 
confirmed with multiplex and monoplex PCR protocols.  Adenovirus accounted for 99 of the 
specimen. Among the specimen that were culture positive for adenovirus, 39 were species B, 54 
were species C, and 1 was species E. Of the HAdV-B, 31 were HAdV-B1 while 8 isolates were 
HAdV-B2. Additionally, 5 samples had co-infections of both HAdV-B and HAdV-C (Figure 5).   
Interspecies and intraspecies co-infections do occur in patients presenting with influenza-
like illness (ILI) in Egypt.   
Molecular typing by PCR, and sequencing of the hexon gene allowed the identification of 
the HAdV-B serotypes as follows: 17 isolates were Ad-3, 14 were Ad-7, 8 were Ad-11 (Figure 
6). For the HAdV-Cs species, 19 isolates were Ad-1,  9 were Ad-2, 13 were Ad-5 and 12 were 
Ad-6. One of the samples in this group also contained a co-infection of Ad-5/Ad-6 (Figure 6). 
The serotypes of the five HAdV-B/HAdV-C co-infections were Ads (3+1) for three cases, while 
the other two were Ads (3+5) and Ads (3+2). The only HAdV-E strain isolated was serotyped to 
the 4a variant. 
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Human adenovirus is circulating in six govenorates of Egypt. 
 Eight collection sites were the source of the isolates from 2003 to 2010 (Table 4). The 
sites were distributed in different locations in Egypt. One site was located on the North Coast 
(Alexandria Fever Hospital), two belonged to the Delta region (Damietta and Sharquia Fever 
Hospitals), three were in Greater Cairo (Helwan, Imbaba and Gabarty  Hospitals) and two were 
suited in Upper Egypt (Menia and Aswan Fever Hospitals). The Alexandria Fever Hospital had 
23 cases of adenovirus infection. There were more HAdV-C (n=14) than HAdV-B cases (n=7). 
Ad-1 and Ad-2 were the major HAdV-C isolates while only Ad-3 represented the HAdV-B 
cases. One co-infection was observed in this group (Ad-3+1). The only HAdV-E strain was also 
isolated from this hospital. Damietta and Sharquia Fever Hospital had only 9 cases; 6 of them 
were HAdV-B species and 3 were HAdV-C. A majority of the adenovirus cases were seen in 
Greater Cairo. Imbaba Fever Hospital had 4 HAdV-B and 1 HAdV-C cases. Al-Gabarty  
Hospitals had 5 HAdV-B and 10 HAdV-C cases with two HAdV-B/HAdV-C co-infections. The 
predominant serotypes from this hospital were Ad-7 (HAdVB) and Ad-5 (HAdVC). Helwan 
Fever Hospital had 18 cases, with more HAdV-B than HAdV-C species infections. 7 of the 
isolates belonged to subgenus B1 (Ad-3 and Ad-7) while 6 of the isolates belonged to subgenus 
B2 (Ad-11a). Only six of the isolates belonged to HAdV-C species. Menia and Aswan Fever 
Hospitals had 27 cases with the majority being HAdV-C. Two Ad3+1 co-infection were detected 
from Aswan. 
Distribution of serotypes according to the isolation years 
Ad-3 isolates were distributed evenly throughout the years starting from 2005 until 2010. 
Ad-7 was detected starting in 2008 and has remained in circulation. Two Ad-11a were isolated in 
2005, and from 2007 until 2010, Ad-11 continued to be in circulation. HAdV-C isolates 
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distribution was uniform throughout the period of collection except for Ad-6; Ad-6 infections 
increased in 2009 and 2010. The only HAdV-E isolate was recovered in April, 2009 (Table 5). 
Adenovirus cases appear to occur in the Spring and Summer months in Egypt 
Forty-six isolates were recovered during April, May and June (Table 6) which represent 
both the Spring and Summer months. Interestingly, adenovirus cases appear to decline during the 
typical influenza season (October-March) (Table 6). 
 
 
Distribution of HAdV species among different age groups  
Forty of the isolates were obtained from infants less than two years of age. Thirty of the 
isolates belonged to HAdV-C with a higher proportion of serotypes being Ad-5 (11 isolates) and 
Ad-1 (9 isolates). Additionally, there was an Ad-5+6 co-infection. Only six isolates were HAdV-
B1. Three HAdV-B+C co-infections were detected. Forty-two isolates were recovered from 
children between 2-18 years of age. Sixteen isolates were HAdV-C; Ad-1 and Ad-6 were the 
prominent serotypes. There were a total of 26 HAdV-B isolates; 19 were HAdV-B1 and 7 
HAdV-B 2. The adult age group (18-56 yrs of age). Eight of the isolates were HAdV-C. Seven of 
the HAdV-B isolates were further classified to HAdV-B1 (Ad3 and Ad7). There were two Ad-
3+1 (Figure 7). 
HAdV-C intraspecies recombinants are in circulation.  
The phylogenetic relationship of HAdV-C isolates in our isolates collection was analysed 
using two regions of their genome: the fibre gene and the HVR-7 of the hexon gene.  All groups 
of HAdV-C serotypes were supported with values of bootstrap at 100%. For the fibre gene, 
XXV 
 
isolates belonging to the same serotype had overall nucleotide differences lower than 1.2 % 
which has been previously described (64). The difference in nucleotide sequences between 
members belonging to different serotypes was high, 28.2-68.1% indicating expected 
heterogeneity of this gene among different HAdV-C serotypes (25). With respect to the HVR-7, 
nucleotide differences for isolates belonging to the same serotype of Ad-1, 2, and 5 were less 
than 6%, except in rare cases where some isolates belonging to the same serotypes had 
differences of up to 11.5%. 75% nucleotide differences were observed for isolates belonging to 
different serotypes. We compared the phylogenetic relationships between the fibre and the HVR-
7 trees constructed. Ad-1 and Ad-5 grouped together in both cases. However, Ad-6 results were 
not similar in both trees. In the fibre gene phylogenetic tree, the Ad-6 isolates grouped together 
with their reference. But in the HVR-7 tree, 10 out of the 12 Ad-6 isolates grouped with Ad-2 
isolates. BLAST and bioinformatic analysis revealed that these 10 isolates’ genome consisted of 
an Ad-6 fibre gene and an Ad-2 HVR-7, thus indicating an intermediate strain. The other two 
Ad-6 isolates grouped together with the Ad-6 reference sequence (Figure 8). Sequencing the 
fibre gene of isolates belonging to the four HAdV-C serotypes confirmed some interesting 
findings about this important viral capsid protein. Isolates belonging to the same serotype 
showed high degree of homogeneity at the nucleotides level (99%) and even higher degree at the 
amino acids level. As for isolates belonging to different serotypes, these showed high degree of 
heterogeneity, as mentioned earlier, but the heterogeneity is mainly seen in the shaft and the 
knob regions of the fibre gene (Figure 9).  
HAdV-C fibre protein had conserved sequences in the tail. 
 At the nucleotide level, the fibre tail (132 nucleotides) showed 21 nucleotide differences 
(~15%) among the four serotypes. However, the nucleotide substitutions did not result in any 
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changes at the amino acids level where the forty four amino acids comprising the fibre tail are 
the same in the 53 isolates. The two conserved motifs “KRAR” and “FNPVYPYD” which are 
located in the fibre tail were 100% homologous in all 53 isolates.  
Fibre shaft length is similar among different serotypes.  
Fibre shaft length was found to be similar in length (357 amino acids; 1071 nucleotides) 
in Ad-1, -2 and -5. The shaft of Ad-6 consisted of 306 amino acids due to deletions in some shaft 
repeats. In the shaft region, the nucleotide difference ranged from 24-40.3% for isolates 
belonging to different serotypes. Whereas at the amino acid level, the difference ranged from 
27.6-43.4%. These findings indicate that mutations occurring in this region were in most cases 
non-synonymous.  
 
HAdV-C fibre shaft residues used for attachment to HS-GAGs are conserved.  
The basic “KKTK” motif responsible for attachment to the acidic HS-GAGs receptor was 
found to be consistent in 47 out of the 53 HAdV-C isolates. Interestingly, there were six isolates 
(Ad-2) with modifications. These solates have the fourth residue “K” (Lysine) replaced by the 
basic “N” (Asparginine) residue; however, this substitution still maintains the ability of the motif 
to perform its function.  At the nucleotides level, the mutation was due to a single transversion 
where guanine was replaced by thymine. 
HAdV-C fibre knob.  
The fibre knob showed a similar degree of heterogeneity to that seen in case of the fibre 
shaft where on the nucleotides level the difference ranged from 26.4-32.6%. Similar results were 
obtained when aligning the encoded amino acids. 
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DISCUSSION 
 Adenoviruses are able to infect a wide range of hosts and their organ systems (8). In this 
retrospective study, we concentrated on further characterizing adenovirus isolates in our 
collection derived from an influenza-like illness surveillance program that NAMRU-3 conducts 
in concert with the Ministry of Health and Population from 2003-2010. This study builds on 
knowledge gleaned from previous work conducted by Metzgar et al in 2005 who examined 
isolates in the collection from 1999 to 2002 (75). The current study indicates that adenoviruses 
are indeed still in circulation in Egypt and that the recognized clinically important HAdV-B and 
C species do appear to continue to play a role in active respiratory disease. In contrast to the 
earlier manuscript’s results, HAdV-C species, rather than HAdV-B1, were recovered in higher 
proportion, particularly from patients between the ages of 0-2 years (Figure 7).  HAdV-Cs were 
detected in patients sampled in the Delta, Greater Cairo and Upper Egypt regions (Table 4). 
HAdV-Bs were especially prominent in Greater Cairo and targeted patients between the ages of 
2-18 (Figure 7). HAdV-B species typically causes more severe clinical disease and it is possible 
that the metropolitan hospitals were preferentially selected for more comprehensive care. 
Several studies have demonstrated that adenovirus, particularly HAdV-Cs, do have the 
capacity, at low titers, to persist in the lymphoid tissues of their host or cause a latent infection 
similar to that of herpesviruses (32, 35, 45, 71). In fact, this property actually facilitated the 
discovery of adenoviruses in the first place (93). Studies in the 1960s and 70s demonstrated that 
children exposed to HAdV-Cs may continue to shed the virus in the absence of any identifiable 
clinical diseases (13, 32). Taking into account this viral strategy, some might argue that the 
results cannot definitively demonstrate a causal and effect link between the strains detected and 
the clinical manifestations of influenza-like illness. However, the patients sampled did fulfill the 
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case definition, isolates were recovered and other etiologies were excluded. Our work is a start in 
understanding the endemicity of HAdV-C strains and their ability to cause long-term sub-clinical 
infection in Egypt. In the future, prospective studies that incorporate a rigorous epidemiological 
analyses will be beneficial to addressing this question. 
 Ad1 was the most common HAdV-C serotype identified, followed by Ad5 and Ad6. 
Compared to Ad1 and Ad5, in vitro studies have shown that Ad6 serotypes are at a disadvantage 
during the infection cycle due to their shorter fibre length (528 aa residues vs. 582 aa residues of 
the other serotypes)(131). Fibre length is important for attachment to more than one receptor on 
the cellular surface during viral entry. The longer and more flexible the fibre protein, the more 
probable the HAdV can cause infections (98). Reports indicate that Ad-6 causes only 0.67% of 
ARD observed due to HAdV (25). In this study, we observed that 10/12 Ad6 isolates were 
intermediate recombinants (in association with Ad2) and that one co-infection occurred with 
Ad5. The recombination event, however, do not improve fibre length since the intermediate 
strains consists of the Ad6 fibre gene and the Ad2 HVR-7 of the hexon. Although the 
recombination event does not appear to confer a structural advantage, there is the possibility that 
it might in fact provide a means for either a more efficient infection and/or ability to evade the 
immune response. More studies are required to understand the virulence properties of this strain 
in relation to the wild-type parental strains. While it is difficult to pin-point the evolutionary 
advantage of the described recombination event noted in this study, it is plausible to attribute 
both the recombination and co-infection interactions to the persistence and latency properties 
attributed to HAdV-C strains. 
 For the HAdV-B1, Ad3 and Ad7 continue to be the predominant serotypes as expected 
(75). With respect to the co-infections, Ad3 was the primary player where HAdV-B was 
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involved. Interestingly, this study recovered 8 Ad11a (HAdV-B2) serotypes, predominantly from 
the Greater Cairo region. Although Ad11s have been isolated from respiratory, ocular and 
gastrointestinal diseases (8, 75, 97), they are typically better known for their role in causing acute 
hemorrhagic cystitis in young males (78, 82), immunocompromised patients and renal 
transplantation recipients (36, 38, 61). Additional studies are warranted to explain the emergence 
of this serotype in respiratory pathogenesis. This finding highlights the diversity in tissue tropism 
of some serotypes.  
Additional studies are also required to explain why different numbers of isolates were isolated 
from the three cell lines that were used. 
 Several different serotypes of adenoviruses are circulating within the human population 
of Egypt. As mentioned above, some serotype show an impressive array of tissue tropism. 
Medical and public health officials in Egypt should include adenoviruses as potential pathogens 
on their differential lists when considering ailing or immunocompromised patients exhibiting 
pneumonia, acute febrile pharyngitis, acute respiratory disease, epidemic keratoconjunctivitis, 
acute hemorrhagic cystitis, or gastroenteritis. Clearly, dentifying the serotypes responsible for 
disease patterns before executing control measures such as vaccine prophylaxis is warranted.  
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CONCLUSIONS 
 In this study, we used genetic approaches to characterize the contribution of adenovirus 
to the burden of influenza-like illness in the Nile Delta region of Egypt from 2003-2010. Human 
adenovirus C (HAdVC) plays a prominent role in causing morbidity among both pediatric and 
adult patients presenting with respiratory disease. Co-infections continue to occur within the 
population and should be monitored if vaccine prevention measures are to be implemented. 
Additionally, it is quite clear that intertypic recombinants do occur amongst the adenovirus 
strains that are in circulation in Egypt. Additional studies are urgently needed to evaluate the 
pathogenicity of variant strains against known wild type strains (e.g. develop animal model of 
infections); to determine novel markers of antiviral resistance within both animal and human 
hosts, and to define possible vaccine candidate components that would be effective for the 
region. 
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TABLES 
Table 1. Classification of Human Adenoviruses (HAdV).  
Different serotypes belong to each species. Initial classification was done based on different 
characteristics including their HA profile (8). 
Species Serotypes 
A 12, 18, 31 
B B1 3, 7, 16, 21, 50 
B2 11, 14, 34, 35 
C 1, 2, 5, 6 
D 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-
39,42-49, 51 
E 4 
F 40, 41 
G 52 
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Table 2. Oligonucleotides used for identification, species and serotype determination of 
HAdV isolates. Primers were obtained from previously published studies. Most of the primers 
used target either the hexon or the fibre genes. Although most of them were originally used as 
multiplex PCR reactions, we had to make some modifications in some of those reactions due to 
appearance of non-specific bands in the gels obtained and to confirm co-infections. 
 
Primers Names Primer Sequence Target Amplicon  Reference 
Ad-1 (F) 
Ad-2 (R) 
TTCCCCATGGCICAYAACAC 
CCCTGGTAKCCRATRTTGTA 
Hexon 482 (142) 
BCE multiplex 
HAdV-B (F) 
HAdV-B (R) 
CGGAGCT(G/T)CCTGGACATG 
GCTTAGGCTTCACAGGAATG 
E1A 319 (74) 
HAdV-C (F) 
HAdV-C (R) 
GGTGATCGATCTTACCTGC 
CTCAGGAGGTGTGTTAGAAGG 
E1A 410 (74) 
HAdV-E (F) 
HAdV-E(R) 
CTGCACGATTTGTATGATCTGG 
CCTGCTCGTICTCATCATCG 
E1A 222 (4a) 
255 (4p) 
(74) 
B/C/E (to confirm coinfections) 
HAdV-B1 
HAdV-B2 
TSTACCCYTATGAAGATGAAAGC 
GGATAAGCTGTAGTRCTKGGCAT 
Fibre  670-772 (142) 
HAdV-C1 
HAdV-C2 
TATTCAGCATCACCTCCTTTCC  
AAGCTATGTGGTGGTGGGGC 
Fibre 1988–
2000 
(142) 
HAdV-E1 
HAdV-E2 
TCCCTACGATGCAGACAACG 
AGTGCCATCTATGCTATCTCC 
Fibre 967 (142) 
Ad-3/Ad-7/Ad-21 multiplex 
Ad-3 F 
Ad-3 R 
GGTAGAGATGCTGTTGCAGGA  
CCCATCCATTAGTGTCATCGGT  
Hexon 502 (75) 
Ad-7 F  
Ad-7 R  
GGAAAGACATTACTGCAGACA 
AATTTCAGGCGAAAAAGCGTCA 
Hexon 311 (75) 
Ad-21 F  
Ad-21 R  
GAAATTACAGACGGCGAAGCC 
AACCTGCTGGTTTTGCGGTTG 
Hexon 237 (75) 
Ad-11 
Ad-11 F Ad-11 
R  
GAAGTTTCAGATGAAGAAAGTA 
AGGACTTAAGTTTGTTTTCTGC 
Hexon 293 (74) 
Ad-14 
Ad-14 F 
Ad-14 R 
AAATGCTAATCTTGGACAGCAGTC 
AGCCGTCCAGTGGAAAACAGTAGT 
Hexon 324 (74) 
HAdV-C serotyping 
HAdV-C (F) TGC TTG CGC THA AAA TGG GCA Fibre   (3) 
HAdV-C1 (R) CGA GTA TAA GAC GCC TAT TTA CA Fibre  630 (3) 
HAdV-C2 (R) CGC TAA GAG CGC CGC TAG TA Fibre 204 (3) 
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HAdV-C5 (R) ATG CAA AGG AGC CCC GTA C Fibre 455 (3) 
HAdV-C6 (R) CTT GCA GTCTTTATCTGAAGCA Fibre 929 (3) 
HVR-7 primers for sequencing  
HVR (F) 
HVR (R) 
CTGATGTACTACAACAGCACTGGCAACATG
GG 
GCGTTGCGGTGGTGGTTAAATGGGTTTAC 
HVR7 PCR= 600 (108) 
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Table 3. Oligonucleotides used for sequencing the fibre genes of the four HAdV-C types 
(Ad-1, 2, 5, and 6). An average of eight primers (four forward and four reverse) were used in 
sequencing the fibre gene of each serotype. Primer3 v0.4.0 software was used for primers design 
based upon reference sequences of the fibre gene of each serotype obtained from Genbank. 
Ad-1 fibre sequencing primers   
Primers Names Primers Seuqence Tm Source  
Ad1-F370 CTCACAGTTACATCAGGCATTC 57 this work 
Ad1-F800 GTTACAGGCGCAATAGGG 57 this work 
Ad1-F1200 AAACTTGGAACAGGCCTTAG 56 this work 
Ad1-F1525 AACGCTACAGCATATACTAACG 55 this work 
Ad1-F1728 TTCATGGAGCTGGCCTA 56 this work 
Ad1-R300 AGGTTGCCGGCCTTG 59 this work 
Ad1-R700 CGTGAGAGTCGTTGGTCAC 57 this work 
Ad1-R1180 ATACCACCGTTTGAGTCATAGTC 57 this work 
Ad1-R1715 TATGTACTGGCGGGAGTG 56 this work 
Ad1-R1560 AACTGCGTTAGTATATGCTGTAG 54 this work 
Ad-2 fibre sequencing primers   
Primers Names Primers Sequence Tm   
Ad2-F360 GATAGTTACTAGCGGCGCTCT 58 this work 
Ad2-F780 GCGGTGGCATGCGTA 59 this work 
Ad2-F802 GATGTGGATTACCCATTTG 54 this work 
Ad2-F1200 ACTTACCCTGTGGACAACC 55 this work 
Ad2-F1500 AGTTGGATTTATGCCTAACC 54 this work 
Ad2-R385 CGCTAAGAGCGCCGCTAGTA 63 this work 
Ad2-R1400 GAGTTCCCATTTCTAAAGTTCC 56 this work 
Ad2-R1100 CATTGTAATCAATGCCAGAG 54 this work 
Ad2-R700 AACGGTGACACCTGGTC 55 this work 
Ad-5-fibre sequencing primers   
Primers Names Primers Sequence Tm   
Ad5-F370 GCGGGCAACACACTCA 58 this work 
Ad5-F780 GCAGGAGGACTAAGGATTGA 57 this work 
Ad5-F1150 GACAGCACAGGTGCCAT 56 this work 
Ad5-F1500 GTTGGATTTATGCCTAACCT 54 this work 
Ad5-R1600 TGTCTCCTGTTTCCTGTGTA 54 this work 
Ad5-R1200 TGGAGCTGGTGTGGTC 54 this work 
Ad5-R800 GAATCAATCCTTAGTCCTCCT 54 this work 
Ad5-R400 TGCATGGTGAGTGTGTTG 54 this work 
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Ad-6 fibre sequencing primers   
Primers Names Primers Sequence Tm   
Ad6-F430 CTAACCATGGCCACAACT 54 this work 
Ad6-F800 GTTACAGGCGCAATAGG 53 this work 
Ad6-F1200 GCTAACTCTGGCGCTAACA 57 this work 
Ad6-F1600 GTCCTGGAACAGTGGACA 55 this work 
Ad6-R400 AGCGGTTGAGAAACAGTG 55 this work 
Ad6-R800 ACCCTATTGCGCCTGT 55 this work 
Ad6-R1200  CTTGCAGTCTTTATCTGAAGCA 58 this work 
Ad6-R1600 CCAGGACCAACTGAATGA 55 this work 
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Table 4. Isolates’ serotypes and their geographical origin. 
 
AdB  AdC  AdE  
HAdV  
B+C  Ad-3  Ad-7  Ad-11  Ad-1  Ad-2  Ad-5  Ad-6  Ad-5+6  Ad-4  
Alex.  7  
  
6  5  2  1  
 
1  1  
Delta  2  3  1  3  
      
Greater Cairo  6  8  7  5  3  6  3  
  
2  
Upper Egypt  2  3  
 
5  1  5  8  1  
 
2  
 
 
 
Table 5. Yearly distribution of different HAdV serotypes isolated from 2003 to 2010.  
HAdV-B isolates are more than those of HAdV-C during 2005 and 2009. However, in all the 
other collection years, HAdV-C isolates were more abundant. Most of Ad-6 isolates were 
recovered in 2009 and 2010. 
Serotypes Isolates/year 
Year Ad-3 Ad-7 Ad-11 Ad-1 Ad-2 Ad-5 Ad-6 Ad-4 
2003    1   1  2 
2004         0 
2005 2  2   1   5 
2006 3   2 1 1 1  8 
2007 2  1 3 1 3   10 
2008 3 4 1  2    10 
2009 6 5 1 6  4 5 1 28 
2010 6 5 3 10 6 6 6  42 
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Table 6. Seasonal distribution of HAdV infections in Egypt from 2003 to 2010. In April, 
May and June, the highest number of isolates were recovered.  
Year Jan Feb Mar Apr May June July Aug Sep Oct Nov Dec 
2003    2         
2004             
2005      1  2  1   
2006   1    1  1  3 2 
2007 1 2 1   6       
2008     2  1 3  1 1 1 
2009 1 2 5 5 3 4 1   2 2 2 
2010  4 5 7 9 7 4 2     
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FIGURE LEGENDS 
Figure 1. Structure of HAdV particle with capsid and core proteins (63).  
The HAdV particle has an icosahedral structure. Hexons are the major proteins in the capsid 
while pentons are located in the vertices and fibres project from them. Due to the hexon 
molecules’ different environment in the viral capsid, hexons are divided into H1; the 
peripentonal hexon, H2, H3 and H4. Protein IX can ve viewed when from the outer surface while 
proteins IIIa, VI and VIII can be seen if we look from the internal surface. Other proteins are 
distributed according to their proposed functions. . 
Figure 2. The trimeric structure of the C-terminal of the fibre protein (98).  
The fibre knob is the first structure that interacts with the attachment receptors on the cell. This 
figure annotates the important loops protruding from the knob which form what is known as the 
γ-determinant (98). The fibre knob has seven important variable loops (FG, HI, DE, AB, CD, IJ 
and GH). The identity and physicochemical properties of the amino acids in these loops 
determines the ability of different serotypes to interact with different cellular receptors. Fibre 
proteins belonging to the same serotype show high degree of homology whereas those belonging 
to different serotypes, even those of the same species, show high degree of heterogeneity 
specifically in the shaft and knob regions of the protein.  
Figure 3. Identification of HAdV in cells using immunoflourescence.  
(A) Positive IFA test for the presence of adenovirus, (B) Negative control. The commercial kit is 
LIGHT DIAGNOSTICS™, Millipore (Cat# 3105). 
Figure 4.  Ad-3/7 multiplex PCR gel electrophoresis. 
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PCR products were analyzed on a 2.5% agaros gel. Difference in bands size and specificity of 
the primers allowed correct identification of the isolates type. The band size of Ad-7 was 311 bp 
whereas that of Ad-3 band size was 502 bp. Positive control for Ad-7 is indicated by Ad7 +C. 
Positive control for Ad-3 is indicated by Ad-3+C.  Negative control is indicated by –C.  
Figure 5. Speciation of HAdV isolates from 2003 to 2010. 
54 isolates proved to be HAdV-C, 39 isolates are HAdV-B, 1 isolate is HAdV-E while 7 samples 
represent co-infections by two different serotypes. This contribution of different species to our 
collection is concordant with earlier studies in different regions in the world. 
Figure 6. Serotyping of HAdV isolates from 2003 to 2010. 
Ad-1 participates by 19 cases, so it is considered the most represented serotype. Ad-3 is the most 
abundant HAdV-B serotype in our collection. Ad-6 is represented by 12 cases which is 
considered a high percentage compared to its well known prevalence rate (0.67% of ARD caused 
by HAdV). 
Figure 7. The distribution of HAdV isolates among different age groups . 
More HAdV-C than HAdV-B isolates are found in infants, age 0-2 years whereas in children 
ages 2-18 years, there are more HAdV-B isolates. In the 18-56 years age group similar number 
of cases are found. Interestingly, three cases of HAdV-B/HAdV-C co-infections are found in the 
0-2 years age group. 
Figure 8. Phylogenetic relationships of HAdV-C isolates examining the fibre gene and the 
hypervariable region 7 of the hexon gene. 
The trees were constructed using MEGA4 software, utilizing the neighbour-joining method and 
maximum composition likelihood model for nucleotide substitution. Bootstrap analysis was 
implemented with 1000 replicates. The fibre gene tree (A) shows perfect grouping of all isolates 
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belonging to same serotype together with their reference strain sequences. The HVR-7 tree (B) 
shows grouping of 10 of the 12 Ad-6 isolates together with the Ad-2 isolates and reference strain 
indicating an intermediate recombinant 
 
Figure 9. Amino Acid Sequence Alignment of the fibre protein from four HAdV-C 
serotypes. 
The fibre gene sequence of two of the isolates belonging to each serotype was chosen as 
representative of each type. Bioedit7.0.4.1 software was used to translate and align the predicted 
amino acids sequences of the genes. The protein is divided into three structural domains: Tail, 
Shaft and Knob. The tail is highly conserved among the four serotypes, as shown. Conserved 
motifs in the tail regions are marked. The difference in the shaft region is particularly noticed in 
Ad-6 isolates which have a shorter fibre shaft than the other three serotypes. The “KKTK” which 
is a basic motif in the fibre shaft used for attachment to the acidic HS-GAGs receptors on cell 
surface is conserved in Ad-1, -2 and -6. In Ad-2, the last “K” amino acid is replaced by another 
basic amino acid “N” which maintains the ability of the motif to perform its function. 
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Figure 1. Structure of HAdV particle with capsid and core proteins (63). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LI 
 
Figure 2. The trimeric structure of the C-terminal of the fibre protein (98).  
 
 
 
 
 
 
 
 
 
Figure 3. IFA test used for initial identification of HAdV in cells.  
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Figure 4.  A multiplex PCR for Ad-3/Ad-7 identification. 
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Figure 5. The number of HAdV isolates belonging to each species.  
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Figure 6. The number of cases in the collection caused by each HAdV serotype. 
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Figure 7. The distribution of HAdV isolates in different age groups.  
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Figure 8. Phylogenetic relationships of all HAdV-C isolates in the collection obtained from 
2003 to 2010 in two regions. 
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Figure 9. Alignment of the fibre protein from the four HAdV-C serotypes. 
Fibre tail: 
 
             ....|....| ....|....| ....|....| ....|....| .... 
                      10         20         30         40             
Ad1_907552   MKRARPSEDT FNPVYPYDTE TGPPTVPFLT PPFVSPNGFQ ESPP 
Ad1_905602   MKRARPSEDT FNPVYPYDTE TGPPTVPFLT PPFVSPNGFQ ESPP 
Ad2_907716   MKRARPSEDT FNPVYPYDTE TGPPTVPFLT PPFVSPNGFQ ESPP 
Ad2_906724   MKRARPSEDT FNPVYPYDTE TGPPTVPFLT PPFVSPNGFQ ESPP 
Ad5_906477   MKRARPSEDT FNPVYPYDTE TGPPTVPFLT PPFVSPNGFQ ESPP 
Ad5_904873   MKRARPSEDT FNPVYPYDTE TGPPTVPFLT PPFVSPNGFQ ESPP 
Ad6_911970   MKRARPSEDT FNPVYPYDTE TGPPTVPFLT PPFVSPNGFQ ESPP 
Ad6_905614   MKRARPSEDT FNPVYPYDTE TGPPTVPFLT PPFVSPNGFQ ESPP 
 
 
Fibre shaft: 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50              
Ad1_907552   GVLSLRLSEP LVTSHGMLAL KMGSGLTLDE AGNLTSQNIT TVTEPLKKTK  
Ad1_905602   GVLSLRLSEP LVTSHGMLAL KMGSGLTLDE AGNLTSQNIT TVTEPLKKTK  
Ad2_907716   GVLSLRVSEP LDTSHGMLAL KMGSGLTLDK AGNLTSQNVT TVTQPLKKTN  
Ad2_906724   GVLSLRVSEP LDTSHGMLAL KMGSGLTLDK AGNLTSQNVT TVTQPLKKTN  
Ad5_906477   GVLSLRLSEP LVTSNGMLAL KMGNGLSLDE AGNLTSQNVT TVSPPLKKTK  
Ad5_904873   GVLSLRLSEP LVTSNGMLAL KMGNGLSLDE AGNLTSQNVT TVSPPLKKTK  
Ad6_911970   GVLSLRLSEP LVTSHGMLAL KMGSGLSLDQ AGNLTSNTIT ~VSEPLKKTK  
Ad6_905614   GVLSLRLSEP LVTSHGMLAL KMGSGLSLDQ AGNLTSNTIT ~VSEPLKKTK  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
Ad1_907552   SNISLETSAP LTVTSGILTV ATAAPLVVAG NSLTVQSQAP LTVQDSKLSI  
Ad1_905602   SNISLETSAP LTVTSGILTV ATAAPLVVAG NSLTVQSQAP LTVQDSKLSI  
Ad2_907716   SNISLDTSAP LTITSGALTV ATTAPLIVTS GALSVQSQAP LTVQDSKLSI  
Ad2_906724   SNISLDTSAP LTITSGALTV ATTAPLIVTS GALSVQSQAP LTVQDSKLSI  
Ad5_906477   SNINLEISAP LTVTSEALTV AAAAPLMVAG NTLTMQSQAP LTVHDSKLSI  
Ad5_904873   SNINLEISAP LTVTSEALTV AAAAPLMVAG NTLTMQSQAP LTVHDSKLSI  
Ad6_911970   SNITLETSAP LTVSSGALTM ATTSPLVVSD NTLTMQSQAP LTVQDSKLSI  
Ad6_905614   SNITLETSAP LTVSSGALTM ATTSPLVVSD NTLTMQSQAP LTVQDSKLSI  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
Ad1_907552   ATKGPLTVSE GKLALQTSGP LSATDNNTLT ITTSPPITTT NGSLGVNMEN  
Ad1_905602   ATKGPLTVSE GKLALQTSGP LSATDNNTLT ITTSPPITTT NGSLGVNMEN  
Ad2_907716   ATKGPITVSD GKLALQTSAP LSGSDSDTLT VTATPPLTTA TGSLGINMED  
Ad2_906724   ATKGPITVSD GKLALQTSAP LSGSDSDTLT VTATPPLTTA TGSLGINMED  
Ad5_906477   ATQGPLTVSE GKLALQTSGP LTTTDSSTLT IAASPPLTTA TGSLGIDLKE  
Ad5_904873   ATQGPLTVSE GKLALQTSGP LTTTDSSTLT IAASPPLTTA TGSLGIDLKE  
Ad6_911970   ATKEPLTVLD GKLALQTSAP LSATDNNALT ITASPPLTTA NGSLAVTMEN  
Ad6_905614   ATKEPLTVLD GKLALQTSAP LSATDNNALT ITASPPLTTA NGSLAVTMEN  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
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                     160        170        180        190        200         
Ad1_907552   PLYNSNGKLG LRVAGPLQVT NDSHALTVGT GQGVAIDNNA LHTKVTGAIG  
Ad1_905602   PLYNSNGKLG LRVAGPLQVT NDSHALTVGT GQGVAIDNNA LHTKVTGAIG  
Ad2_907716   PIYVNNGKIG IKISGPLQVA QNSDTLTVVT GPGVTVEQNS LRTKVAGAIG  
Ad2_906724   PIYVNNGKIG IKISGPLQVA QNSDTLTVVT GPGVTVEQNS LRTKVAGAIG  
Ad5_906477   PIYTQNGKLG LKYGAPLHVT DDLNTLTVAT GPGVTINNTS LQTKVTGALG  
Ad5_904873   PIYTQNGKLG LKYGAPLHVT DDLNTLTVAT GPGVTINNTS LQTKVTGALG  
Ad6_911970   PLYNNNGKLG LKIGGPLQVA TDSHALTLGT GQGVAVHNNL LHTKVTGAIG  
Ad6_905614   PLYNNNGKLG LKIGGPLQVA TDSHALTLGT GQGVAVHNNL LHTKVTGAIG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     210        220        230        240        250         
Ad1_907552   YDTSGNMELK TGGGVRVDSV NRRLILDVDY PFDAQSQLRL KLGQGPLYVN  
Ad1_905602   YDTSGNMELK TGGGVRVDSV NRRLILDVDY PFDAQSQLRL KLGQGPLYVN  
Ad2_907716   YDSSNNMEIK TGGGMRINN~ ~NLLILDVDY PFDAQTKLRL KLGQGPLYIN  
Ad2_906724   YDSSNNMEIK TGGGMRINN~ ~NLLILDVDY PFDAQTKLRL KLGQGPLYIN  
Ad5_906477   FDSQGNMQLN VAGGLRIDSQ NRRLILDVSY PFDAQNQLNL RLGQGPLFIN  
Ad5_904873   FDSQGNMQLN VAGGLRIDSQ NRRLILDVSY PFDAQNQLNL RLGQGPLFIN  
Ad6_911970   FDTSGNMELK TGDGLYVDX~ ~~~~~~~~~~ ~~~~~~~~~~ RXGPNXX~~~  
Ad6_905614   FDTSGNMELK TGDGLYVDX~ ~~~~~~~~~~ ~~~~~~~~~~ RXGPNXX~~~  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     260        270        280        290        300         
Ad1_907552   SSTHNLDLNY NKGLHLFTTG N~SKKLEVNL KTTKGLIFDT DAVAINAAQG  
Ad1_905602   SSTHNLDLNY NKGLHLFTTG N~SKKLEVNL KTTKGLIFDT DAVAINAAQG  
Ad2_907716   ~ASHNLDINY NRGLYLFNAS NNTKKLEVSI KKSSGLNFDN TAIAINAGKG  
Ad2_906724   ~ASHNLDINY NRGLYLFNAS NNTKKLEVSI KKSSGLNFDN TAIAINAGKG  
Ad5_906477   SXXHDLDINY NKGLYLFTAS NNSKKLEVNL STAKGLMFDA TAIAINAGDG  
Ad5_904873   SXXHDLDINY NKGLYLFTAS NNSKKLEVNL STAKGLMFDA TAIAINAGDG  
Ad6_911970   ~~~~~~~~~~ ~~~~~~~~~~ ~~~~KLHINL NTTKGLAFDN TAITINAGKG  
Ad6_905614   ~~~~~~~~~~ ~~~~~~~~~~ ~~~~KLHINL NTTKGLAFNN TAITINAGKG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     310        320        330        340        350         
Ad1_907552   LEFGNDTSX~ XNTNPLKTKL GLGLDYDSNG GMIPKLGTGL SFDTTGAITV  
Ad1_905602   LEFGNDTSX~ XNTNPLKTKL GLGLDYDSNG GMIPKLGTGL SFDTTGAITV  
Ad2_907716   LEFDTNTSES PDINPIKTKI GSGIDYNENG AMITKLGAGL SFDNSGAITI  
Ad2_906724   LEFDTNTSES PDINPIKTKI GSGIDYNENG AMITKLGAGL SFDNSGAITI  
Ad5_906477   LEFGSPNAX~ XNTNPLKTKI GHGLEFDSNK AMVPKLGTGL SFDSTGAITV  
Ad5_904873   LEFGSPNAX~ XNTNPLKTKI GHGLEFDSNK AMVPKLGTGL SFDSTGAITV  
Ad6_911970   LEFETDSXX~ ~NGNPIKTKI GSGIQYDTNG AMVAKLGTGL SFDSSGAITM  
Ad6_905614   LEFETDSXX~ ~NGNPIKTKI GSGIQYDTNG AMVAKLGTGL SFDSSGAITM  
 
 
             ....|....|  
                     360  
Ad1_907552   GNKSDDKLTL  
Ad1_905602   GNKSDDKLTL  
Ad2_907716   GNKNDDKLTL  
Ad2_906724   GNKNDDKLTL  
Ad5_906477   GNKNNDKLTL  
Ad5_904873   GNKNNDKLTL  
Ad6_911970   GSINNDRLTL  
Ad6_905614   GSINNDRLTL  
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Fibre knob: 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50              
Ad1_907552   WTTPDPSPNC QIYSEKDAKL TLVLTKCGSQ ILATVSALAV KGSLAPISGT  
Ad1_905602   WTTPDPSPNC QIYSEKDAKL TLVLTKCGSQ ILATVSALAV KGSLAPISGT  
Ad2_907716   WTTPDPSPNC RIHSDNDCKF TLVLTKCGSQ VLATVAALAV SGDLSSMTGT  
Ad2_906724   WTTPDPSPNC RIHSDNDCKF TLVLTKCGSQ VLATVAALAV SGDLSSMTGT  
Ad5_906477   WTTPAPSPNC RLNAEKDAKL TLVLTKCGSQ ILATVSVLAV KGSLAPISGT  
Ad5_904873   WTTPAPSPNC RLNAEKDAKL TLVLTKCGSQ ILATVSVLAV KGSLAPISGT  
Ad6_911970   WTTPDPSPNC RIASDKDCKL TLALTKCGSQ ILGTVSALAV SGNMASINGT  
Ad6_905614   WTTPDPSPNC RIASDKDCKL TLALTKCGSQ ILGTVSALAV SGNMASINGT  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                      60         70         80         90        100             
Ad1_907552   ISSAHIILRF NEHGVLMNNS GLDPQYWNFR KGDLTNATAY TNAVGFMPNL  
Ad1_905602   ISSAHIILRF NEHGVLMNNS GLDPQYWNFR KGDLTNATAY TNAVGFMPNL  
Ad2_907716   VASVSIFLRF DQNGVLMENS SLKKHYWNFR NGNSTNANPY TNAVGFMPNL  
Ad2_906724   VASVSIFLRF DQNGVLMENS SLKKHYWNFR NGNSTNANPY TNAVGFMPNL  
Ad5_906477   VQSAHLIIRF DENGVLLNNS FLDPEYWNFR NGDLTEGTAY TNAVGFMPNL  
Ad5_904873   VQSAHLIIRF DENGVLLNNS FLDPEYWNFR NGDLTEGTAY TNAVGFMPNL  
Ad6_911970   LSSVNLVLRF DDNGVLMSNS SLDKQYWNFR NGDSTNGQPY TYAVGFMPNL  
Ad6_905614   LSSVNLVLRF DDNGVLMSNS SLDKQYWNFR NGDSTNGQPY TYAVGFMPNL  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                     110        120        130        140        150         
Ad1_907552   KAYPKTQSRT AKSNIVSQVY LNGEKDKPMT LTITLNGT~D ENQTTPASTY  
Ad1_905602   KAYPKTQSRT AKSNIVSQVY LNGEKDKPMT LTITLNGT~D ENQTTPASTY  
Ad2_907716   LAYPKTQSQT AKNNIVSQVY LHGDKTKPMI LTITLNGTSE STETSEVSTY  
Ad2_906724   LAYPKTQSQT AKNNIVSQVY LHGDKTKPMI LTITLNGTSE STETSEVSTY  
Ad5_906477   SAYPKSHGKT AKSNIVSQVY LNGDKTKPVT LTITLNGT~Q ETGDTTPSAY  
Ad5_904873   SAYPKSHGKT AKSNIVSQVY LNGDKTKPVT LTITLNGT~Q ETGDTTPSAY  
Ad6_911970   KAYPKTQSKT AKSNIVSQVY LNGDKSKPLH FTITLNGT~D XX~TNQVSKY  
Ad6_905614   KAYPKTQSKT AKSNIVSQVY LNGDKSKPLH FTITLNGT~D XX~TNQVSKY  
 
 
             ....|....| ....|....| ....|....| ... 
                     160        170        180       
Ad1_907552   SISFSWSWPS NQTYIGQTFA TNSYTFSYIA QE* 
Ad1_905602   SISFSWSWPS NQTYIGQTFA TNSYTFSYIA QE* 
Ad2_907716   SMSFTWSWES ~GKYTTETFA TNSYTFSYIA QE* 
Ad2_906724   SMSFTWSWES ~GKYTTETFA TNSYSFSYIA QE* 
Ad5_906477   SMSFSWDWSG ~HNYINEIFA TSSYTFSYIA QE* 
Ad5_904873   SMSFSWDWSG ~HNYINEIFA TSSYTFSYIA QE* 
Ad6_911970   SISFSWSWNS ~GQYANDKFA TNSYTFSYIA QE* 
Ad6_905614   SISFSWSWNS ~GQYANDKFA TNSYTFSYIA QE* 
 
 
 
 
 
